+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ALIVUS

Alivus Life Sciences Share Price

₹1,274.10 -35.4 (-2.7%)
55.57% Gain from 52W Low

19 Oct, 2026 3:01 PM (IST)

Alivus Life Sciences live price: ₹1,274.10. It opened at ₹1,310 vs previous close ₹1,310; intraday high/low: ₹1,325/₹1,258. The 50 & 200 DMA stand at ₹1,333.40/₹1,165.80.

Alivus Life Sciences Performance

  • Today's Low
  • ₹1,258
  • Today's High
  • ₹1,325
  • 52 Week Low
  • ₹819
  • 52 Week High
  • ₹1,494
  • Open Price₹1,310
  • Previous Close₹1,310
  • Volume128,649
  • 50 DMA₹1,333.40
  • 100 DMA₹1,262.10
  • 200 DMA₹1,165.80

Alivus Life Sciences Chart

Investment Returns

  • Over 1 Month -10.95%
  • Over 3 Month + 12.42%
  • Over 6 Month + 19.11%
  • Over 1 Year + 37.99%

Smart Investing Starts Here Start SIP with Alivus Life Sciences for Steady Growth!

Invest Now

Alivus Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25.9
  • PEG Ratio
  • 1.2
  • Market Cap Cr
  • 15,642
  • P/B Ratio
  • 4.5
  • Average True Range
  • 43.4
  • EPS
  • 49.1
  • Dividend Yield
  • 0.4
  • MACD Signal
  • -8.2
  • RSI
  • 39.18
  • MFI
  • 39.43

Latest Stock News Updates

Alivus Life Sciences Ltd - 543322 - Announcement Under Regulation 30 Of SEBI (LODR), 2015

Kindly refer the attachment.

Alivus Life Sciences Ltd - 543322 - Announcement Under Regulation 30 Of SEBI (LODR), 2015 - Acquisition.

We would like to inform that the Company has acquired 9.21% stake in Torrent Urja 19 Private Limited.

Alivus Life Sciences Ltd - 543322 - The Company Has Incorporated A Wholly Owned Subsidiary Company In Brazil.

Please find enclosed herewith intimation with respect to incorporation of wholly owned subsidiary of the Company in Brazil.

Alivus Life Sciences Financials

Alivus Life Sciences Technicals

EMA & SMA

Current Price
₹1,274.10
-35.4 (-2.7%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹1,354.30
  • 50 Day
  • ₹1,333.40
  • 100 Day
  • ₹1,262.10
  • 200 Day
  • ₹1,165.80

Resistance and Support

1285.67 Pivot Speed
  • R3 1,366.00
  • R2 1,353.40
  • R1 1,331.40
  • S1 1,296.80
  • S2 1,284.20
  • S3 1,262.20

Alivus Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-30 Quarterly Results
2026-05-14 Audited Results & Final Dividend
2026-01-22 Quarterly Results
2025-11-06 Quarterly Results
2025-08-01 Quarterly Results
Date Purpose Remarks
2026-09-01 FINAL Rs.5.00 per share(250%)Final Dividend
2025-09-01 FINAL Rs.5.00 per share(250%)Final Dividend
2023-10-17 INTERIM Rs.22.50 per share(1125%)Interim Dividend
2023-03-24 INTERIM Rs.21.00 per share(1050%)Interim Dividend
2021-11-23 INTERIM Rs.10.50 per share(525%)Interim Dividend
View Alivus Life Sciences Dividend History Arrow

Alivus Life Sciences Shareholding Pattern

74.85%
12.19%
5.93%
5.29%
1.74%

About Alivus Life Sciences

Alivus Life Sciences is primarily engaged in the development, manufacture, and marketing of active pharmaceutical ingredients. View More
  • NSE Symbol
  • ALIVUS
  • BSE Symbol
  • 543322
  • Executive Director,Managing Director,Chief Executive Officer
  • Yasir Yusufali Rawjee
  • ISIN
  • INE03Q201024

Similar Stocks to Alivus Life Sciences

Alivus Life Sciences FAQs

Alivus Life Sciences share price is ₹1,274 As on 19 October, 2026 | 14:50

The Market Cap of Alivus Life Sciences is ₹15642.3 Cr As on 19 October, 2026 | 14:50

The P/E ratio of Alivus Life Sciences is 25.9 As on 19 October, 2026 | 14:50

The PB ratio of Alivus Life Sciences is 4.5 As on 19 October, 2026 | 14:50

The 52 week High & Low of Alivus Life Sciences is ₹1493.8/₹819 respectively As on 19 October, 2026 | 14:50

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23